Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H13N3O4S |
Molecular Weight | 331.346 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=CC=C3)S1(=O)=O
InChI
InChIKey=QYSPLQLAKJAUJT-UHFFFAOYSA-N
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
Molecular Formula | C15H13N3O4S |
Molecular Weight | 331.346 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00554Curator's Comment: Description was created based on several sources, including
https://www.pfizermedicalinformation.com/en-us/feldene
Sources: http://www.drugbank.ca/drugs/DB00554
Curator's Comment: Description was created based on several sources, including
https://www.pfizermedicalinformation.com/en-us/feldene
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P04040 Gene ID: 847.0 Gene Symbol: CAT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16789438 |
0.414 mM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10381057 |
4.4 µM [IC50] | ||
Target ID: Aminopeptidase activity Sources: https://www.ncbi.nlm.nih.gov/pubmed/26930569 |
70.0 µM [IC50] | ||
Target ID: CHEMBL1743319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25522350 |
73.8 µM [IC50] | ||
Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12511226 |
7.0 µM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10381057 |
1.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FELDENE Approved UseFELDENE is a nonsteroidal anti-inflammatory drug indicated for
Relief of the signs and symptoms of osteoarthritis (OA)
Relief of the signs and symptoms of rheumatoid arthritis (RA) Launch Date3.86812805E11 |
|||
Primary | FELDENE Approved UseFELDENE is a nonsteroidal anti-inflammatory drug indicated for
Relief of the signs and symptoms of osteoarthritis (OA)
Relief of the signs and symptoms of rheumatoid arthritis (RA) Launch Date3.86812805E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27129120 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIROXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
135.8 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27129120 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIROXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27129120 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIROXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Disc. AE: Chest pain, Rash... AEs leading to discontinuation/dose reduction: Chest pain (0.74%) Sources: Page: p.260Rash (0.74%) Vomiting (0.74%) Exanthema (0.74%) Injection site pain (0.74%) |
1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea Sources: Abdominal pain Gastric ulcer Duodenal ulcer |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Disc. AE: Gastrointestinal disorders, Haemorrhage of digestive tract... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (2.6%) Sources: Page: p.158Haemorrhage of digestive tract (0.85%) Headache (0.85%) Oedema (0.85%) Pruritus (0.85%) Erythema facial (0.85%) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Disc. AE: Epigastric discomfort, Diarrhoea... AEs leading to discontinuation/dose reduction: Epigastric discomfort (2.5%) Sources: Page: p.233Diarrhoea (2.5%) Loose stools (2.5%) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (grade 3-5) Sources: Page: p.1Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (serious) Ulceration (serious) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Chest pain | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Exanthema | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Injection site pain | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Rash | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Vomiting | 0.74% Disc. AE |
40 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: multiple Dose: 40 mg, 1 times / day Sources: Page: p.260 |
unhealthy, 19 -74 n = 135 Health Status: unhealthy Condition: Acute sprains|Tendinitis| Low back pain Age Group: 19 -74 Sex: M+F Population Size: 135 Sources: Page: p.260 |
Abdominal pain | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Duodenal ulcer | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Gastric ulcer | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Nausea | Disc. AE | 1800 mg single, oral Overdose |
unhealthy, 54 n = 1 Health Status: unhealthy Condition: Arthralgia Age Group: 54 Sex: F Population Size: 1 Sources: |
Erythema facial | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Haemorrhage of digestive tract | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Headache | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Oedema | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Pruritus | 0.85% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Gastrointestinal disorders | 2.6% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.158 |
unhealthy, 59.7+/-7.4 n = 117 Health Status: unhealthy Condition: Osteoarthritis Age Group: 59.7+/-7.4 Sex: M+F Population Size: 117 Sources: Page: p.158 |
Diarrhoea | 2.5% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Epigastric discomfort | 2.5% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Loose stools | 2.5% Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.233 |
unhealthy, >40 n = 40 Health Status: unhealthy Condition: Osteoarthritis Age Group: >40 Sex: M+F Population Size: 40 Sources: Page: p.233 |
Cardiac thrombosis | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Myocardial infarction | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Perforation of intestine | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Perforation stomach | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Stroke | grade 3-5 Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Bleeding | serious Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Gastrointestinal disorder NOS | serious Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Ulceration | serious Disc. AE |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Osteoarthritis|Rheumatoid arthritis Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Ki 20.5 uM] | ||||
yes [Ki 23 uM] | ||||
yes [Ki 4.88 uM] | ||||
yes [Ki 70.3 uM] | ||||
yes [Ki 84.9 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (pharmacogenomic study) Comment: Higher systemic exposure of piroxicam has been noted in subjects with CYP2C9 polymorphisms compared to normal metabolizer type subject |
|||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Piroxicam-induced renal failure and hyperkalemia. | 1983 Jul |
|
Piroxicam-induced renal failure. | 1983 Nov |
|
Piroxicam-induced renal disease. | 1984 Jan |
|
Piroxicam-induced acute interstitial nephritis and minimal-change nephrotic syndrome. | 1985 |
|
An interaction between lithium carbonate and piroxicam presenting as lithium toxicity. | 1985 Aug |
|
Piroxicam-induced acute renal failure (anuria). | 1985 May |
|
A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. | 1986 Jan |
|
Piroxicam in acute musculoskeletal disorders and sport injuries. | 1987 |
|
Non-steroidal anti-inflammatory drugs: assessment of risks. | 1987 |
|
[Hepatonephritis caused by piroxicam]. | 1987 Oct |
|
[Fatal autoimmune hemolytic anemia probably induced by treatment with piroxicam]. | 1988 Mar 7 |
|
[Acute hemolytic anemia and hepatonephritis caused by piroxicam]. | 1988 Oct-Dec |
|
Piroxicam-induced renal failure following relief of chronic retention. | 1989 Apr |
|
A comparison of tenoxicam and piroxicam in the treatment of rheumatoid arthritis. | 1992 Apr |
|
Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs. | 1994 Dec |
|
Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. | 1995 Oct |
|
Antiinflammatory 4,5-diarylpyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition. | 1995 Sep 29 |
|
Differential effects of nonsteroidal anti-inflammatory drugs on constitutive and inducible prostaglandin G/H synthase in cultured bone cells. | 1997 Aug |
|
Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon. | 1998 Aug 24 |
|
[Cholestatic hepatitis associated with piroxicam use. Case report]. | 1998 May |
|
Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. | 1998 Nov |
|
[Acute hepatic and renal failure due to piroxicam use]. | 2002 Mar |
|
Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. | 2002 Sep |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection. | 2003 Jul |
|
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. | 2003 Nov 14 |
|
Piroxicam gel, compared to EMLA cream is associated with less pain after venous cannulation in volunteers. | 2003 Oct |
|
[Generalized angioedema with capillary leak syndrome after piroxicam use: a case]. | 2003 Sep-Oct |
|
Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. | 2004 Jul 15 |
|
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam. | 2004 Jun |
|
Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. | 2005 Jul |
|
Apoptotic efficacy and inhibitory effect of dexamethasone on matrix metalloproteinase. | 2005 Jul |
|
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. | 2005 Jul 14 |
|
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. | 2005 Jun |
|
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. | 2005 May |
|
Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. | 2005 Nov |
|
The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. | 2005 Sep |
|
Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. | 2006 Aug |
|
Direct binding of Cu(II)-complexes of oxicam NSAIDs with DNA backbone. | 2006 Aug |
|
Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. | 2006 Oct |
|
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. | 2007 Aug |
|
Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. | 2007 Jan |
|
In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
Effect of acetaminophen, a cyclooxygenase inhibitor, on Morris water maze task performance in mice. | 2007 Sep |
|
Piroxicam: restriction of indications: labelling change. Only half-measures. | 2008 Oct |
|
Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. | 2009 |
|
The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells. | 2009 Apr |
|
Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. | 2011 |
|
Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice. | 2011 Jun 10 |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/piroxicam.html
Recommended dose: 20 mg orally once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11728432
Contractions induced by bradykinin in guinea-pig gallbladder smooth muscle strips were significantly attenuated by the cyclooxygenase inhibitor piroxicam (10 muM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:18:17 UTC 2023
by
admin
on
Wed Jul 05 23:18:17 UTC 2023
|
Record UNII |
13T4O6VMAM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AC01
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
WHO-VATC |
QS01BC06
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
NDF-RT |
N0000175722
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
WHO-ATC |
S01BC06
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
NCI_THESAURUS |
C1915
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
WHO-ATC |
M01AC01
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
WHO-ATC |
M02AA07
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
NDF-RT |
N0000000160
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
NDF-RT |
N0000175721
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
WHO-VATC |
QM02AA07
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
||
|
LIVERTOX |
NBK548425
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2210
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
DB00554
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
8249
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
13T4O6VMAM
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
8356
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
M8889
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID5021170
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
1544508
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
36322-90-4
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
7273
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
252-974-3
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
666076
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
54676228
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
68115
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
ALTERNATIVE | |||
|
100000092492
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
SUB127114
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
Piroxicam
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
SUB09936MIG
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
PIROXICAM
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
3713
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
CHEMBL527
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
C751
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
D010894
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY | |||
|
13T4O6VMAM
Created by
admin on Wed Jul 05 23:18:17 UTC 2023 , Edited by admin on Wed Jul 05 23:18:17 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||